Day in the life of a Senior Analyst at redthread
A glimpse into the world of Dr Sachi Sharma, Senior Analyst, as she spills the tea on her daily routines,…
Read more from Day in the life of a Senior Analyst at redthread
What makes a brilliant objection handler? Start with the end in mind!
We’ve seen a few objection handlers in our time. Some good. Some bad. And some just indifferent and generic. Accurate…
Read more from What makes a brilliant objection handler? Start with the end in mind!
Connecting the dots: from standing ovation to patient access
This post includes commentary on publicly available congress data for investigational therapies that do not currently have marketing authorisation. No…
Read more from Connecting the dots: from standing ovation to patient access
Double or quits: why 0.6% might make all the difference for UK commercial viability
Read the details of the UK–US pharma deal and you’ll be struck by the headlines. First increase in the NICE…
Read more from Double or quits: why 0.6% might make all the difference for UK commercial viability
What’s your preference? What the proposed 5L value set means for pharma
The announcement that dominated UK market access conversations in December was the NICE threshold. For the first time since 1999,…
Read more from What’s your preference? What the proposed 5L value set means for pharma
JCA preparedness: Seven critical areas as you prepare for JCA
Since JCA launched earlier this year we’ve learnt a lot. We know who’s in process and who’s assessing the evidence….
Read more from JCA preparedness: Seven critical areas as you prepare for JCA
Challenges for unlocking access in rare diseases
For better or worse, methods for assessing the value of therapies haven’t fundamentally changed for many years. QALYs, ICERs, budget…
Read more from Challenges for unlocking access in rare diseases
Most favoured nation: Europe’s bitter pill to swallow?
Pharmaceutical pricing remains one of the most contentious issues in global healthcare policy. It’s an open secret that the US…
Read more from Most favoured nation: Europe’s bitter pill to swallow?
Solving the comparator conundrum for JCA and HTA
As JCA starts to hit its stride, those pharma companies current in process are finding out how the EU and…
Read more from Solving the comparator conundrum for JCA and HTA
Are you leaving value on the table in your access negotiations?
At redthread, we have a theory that many pharma companies are leaving value on the table when it comes to…
Read more from Are you leaving value on the table in your access negotiations?
How do you solve a problem like the GVD?
Let’s face it, Global Value Dossiers (GVDs) get a bit of a bad rap. Too long, too dry, a tick…
Elevating your JCA submissions from the “meh” to the “marvellous”
As companies begin to tackle the JCA process for real, creating a compelling JCA dossier that doesn’t become unreadable is…
Read more from Elevating your JCA submissions from the “meh” to the “marvellous”
Day in the life of a Senior Analyst at redthread
A glimpse into the world of Dr Sachi Sharma, Senior Analyst, as she spills the tea on her daily routines,…
Read more from Day in the life of a Senior Analyst at redthread
What makes a brilliant objection handler? Start with the end in mind!
We’ve seen a few objection handlers in our time. Some good. Some bad. And some just indifferent and generic. Accurate…
Read more from What makes a brilliant objection handler? Start with the end in mind!
Connecting the dots: from standing ovation to patient access
This post includes commentary on publicly available congress data for investigational therapies that do not currently have marketing authorisation. No…
Read more from Connecting the dots: from standing ovation to patient access
Double or quits: why 0.6% might make all the difference for UK commercial viability
Read the details of the UK–US pharma deal and you’ll be struck by the headlines. First increase in the NICE…
Read more from Double or quits: why 0.6% might make all the difference for UK commercial viability
What’s your preference? What the proposed 5L value set means for pharma
The announcement that dominated UK market access conversations in December was the NICE threshold. For the first time since 1999,…
Read more from What’s your preference? What the proposed 5L value set means for pharma
JCA preparedness: Seven critical areas as you prepare for JCA
Since JCA launched earlier this year we’ve learnt a lot. We know who’s in process and who’s assessing the evidence….
Read more from JCA preparedness: Seven critical areas as you prepare for JCA
Challenges for unlocking access in rare diseases
For better or worse, methods for assessing the value of therapies haven’t fundamentally changed for many years. QALYs, ICERs, budget…
Read more from Challenges for unlocking access in rare diseases
Most favoured nation: Europe’s bitter pill to swallow?
Pharmaceutical pricing remains one of the most contentious issues in global healthcare policy. It’s an open secret that the US…
Read more from Most favoured nation: Europe’s bitter pill to swallow?
Solving the comparator conundrum for JCA and HTA
As JCA starts to hit its stride, those pharma companies current in process are finding out how the EU and…
Read more from Solving the comparator conundrum for JCA and HTA
Are you leaving value on the table in your access negotiations?
At redthread, we have a theory that many pharma companies are leaving value on the table when it comes to…
Read more from Are you leaving value on the table in your access negotiations?
How do you solve a problem like the GVD?
Let’s face it, Global Value Dossiers (GVDs) get a bit of a bad rap. Too long, too dry, a tick…
Elevating your JCA submissions from the “meh” to the “marvellous”
As companies begin to tackle the JCA process for real, creating a compelling JCA dossier that doesn’t become unreadable is…
Read more from Elevating your JCA submissions from the “meh” to the “marvellous”